Silence Therapeutics’ siRNA asset showed hints of efficacy in cardiovascular disease patients enrolled in a Phase I trial amid recent readouts from pipeline rivals backed by Big Pharma companies.
The biotech’s drug, zerlasiran, is designed to lower the body’s production of lipoprotein(a), or Lp(a), which is considered a genetic risk…
Click here to view original post
